登录 | 注册    关注公众号  
微信公众号
搜索
 > 【Glucosylceramidase】

Glucosylceramidase信息

英文名称:Glucosylceramidase
中文名称:葡糖苷酰鞘氨醇酶
靶点别称:Glucosylceramidase
上市药物数量:0
临床药物数量:2
最高研发阶段:临床一期

Glucosylceramidase产品列表

产品库
物种
标签
属性
货号 物种 产品描述 蛋白结构 纯度 活性
GLE-H52H3
Human
Human Glucosylceramidase Protein, His Tag
ACRO质量管理体系
 
评论(0)
 

Glucosylceramidase分子别名

Glucosylceramidase,GBA,Acid beta-glucosidase,Alglucerase,beta-glucocerebrosidase,D-glucosyl-N-acylsphingosine glucohydrolase,EC 3.2.1.45,GBA,GBA1,GC,GCB,GLUC,glucosidase, beta, acid,glucosidase, beta,acid (includes glucosylceramidase),Glucosylceramidase,Imiglucerase,lysosomal glucocerebrosidase

Glucosylceramidase分子背景

Glucosylceramidase that catalyzes, within the lysosomal compartment, the hydrolysis of glucosylceramide/GlcCer into free ceramide and glucose. Thereby, it plays a central role in the degradation of complex lipids and the turnover of cellular membranes. Through the production of ceramides,it participates in the PKC-activated salvage pathway of ceramide formation and plays a role in cholesterol metabolism. It may either catalyze the glucosylation of cholesterol, through a transglucosylation reaction that transfers glucose from glucosylceramide to cholesterol. Defects in Glucosylceramidase are the cause of Gaucher disease, also known as glucocerebrosidase deficiency. Gaucher disease is the most prevalent lysosomal storage disease, characterized by accumulation of glucosylceramide in the reticulo-endothelial system. Currently, enzyme replacement therapy is used to treat patients with the disease.

Glucosylceramidase临床药物信息

英文名称 研发代码 研发阶段 公司 适应症 临床试验
GT-02287 GT-02287 临床一期 Gain Therapeutics Inc 帕金森病 详情
VQ-101 VQ-101 临床一期 Vanqua Bio Inc 帕金森病 详情

消息提示

请输入您的联系方式,再点击提交!

确定